C-Peptide Test

C-peptide is a small protein produced in the pancreas during the creation of insulin. When your pancreas makes insulin, it first produces a larger molecule called proinsulin, which is then split into two parts: insulin and c-peptide. These two are released into the bloodstream in equal amounts. While insulin gets to work lowering blood sugar, c-peptide doesn’t directly affect glucose levels—but it serves as a highly useful marker of how much insulin your body is naturally producing.

This makes c-peptide incredibly valuable in evaluating the health and function of the insulin-producing beta cells in your pancreas. Since injected (or exogenous) insulin does not come with c-peptide, measuring c-peptide allows you to assess your body’s own insulin production, even if you’re taking insulin therapy.

In type 1 diabetes, c-peptide levels are typically very low or undetectable, reflecting near-total beta-cell failure. However, even small amounts of residual c-peptide in people with type 1 diabetes have been linked to better blood sugar control, lower hbA1c, reduced insulin requirements, and fewer complications such as eye or kidney disease. For example, people with detectable c-peptide may experience less glucose variability and fewer episodes of low blood sugar, because their remaining beta cells still respond to rising and falling glucose levels.

In type 2 diabetes, where insulin resistance is the primary issue, c-peptide levels are often normal or elevated—especially in the earlier stages of the disease. Higher levels here may suggest the pancreas is overworking to compensate for insulin resistance. Interestingly, these higher c-peptide levels have been associated with increased cardiovascular risk and mortality, possibly because they reflect a metabolic state of chronic stress. At the same time, modestly higher c-peptide levels may signal a lower risk of kidney decline, suggesting some protective effects depending on context.

C-peptide testing also helps distinguish between other, less common forms of diabetes, such as latent autoimmune diabetes in adults (LADA) or maturity-onset diabetes of the young (MODY), especially when used alongside antibody testing. It’s useful in determining if someone really needs insulin, or if their pancreas is still making enough of its own. This can guide whether a person is more likely to respond to medications like GLP-1 receptor agonists, sulfonylureas, or thiazolidinediones, which require some residual beta-cell function to work.

Different methods exist for measuring c-peptide—such as fasting levels, random samples, or stimulated tests (e.g., after a glucagon injection or a meal). Stimulated tests tend to give the most sensitive picture of how your beta cells function under real metabolic demand. However, people with kidney disease need special consideration, as impaired kidney function can falsely raise C-peptide levels by slowing its clearance.